Abstracts tagged "Eye Disorders"

Abstract Number: 1054 • ACR Convergence 2020
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
José Luis Martín-Varillas¹, Vanesa Calvo-Río², Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon³, Ignacio Torre⁴, Alvaro García Martos⁵, Amalia Sánchez Andrade⁶, Angel García Aparicio⁷, Juan Ramón De dios⁸, Ana Urriticoechea⁹, Olga Maiz Alonso¹⁰, Raul Veroz¹¹, Andrea García Valle¹², Sergio Rodriguez Montero¹³, Roberto Miguelez¹⁴, Vega Jovani¹⁵, Marisa Hernandez Garfella¹⁶, Arantxa Conesa¹⁷, Olga Martinez Gonzalez¹⁸, Paula Rubio Muñoz¹⁹, Eva Peña Sainz-Pardo²⁰, Miguel Ángel González-Gay²¹ and Ricardo Blanco², ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Basurto, Bilbao, Spain, ⁵Hospital del Tajo, Madrid, Spain, ⁶H. Lucus Augusti, Lugo, Spain, ⁷H. Mostoles, Madrid, Spain, ⁸H. Alava, Alava, Spain, ⁹Can Misses, Ibiza, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹H. Mérida, Mérida, Spain, ¹²H. Palencia, Palencia, Spain, ¹³H. Virgen de Valme, Sevilla, Spain, ¹⁴Toledo, Toledo, Spain, ¹⁵H. Alicante, Alicante, Spain, ¹⁶H. Valencia, Valencia, Spain, ¹⁷H. Castellón, Castellón, ¹⁸H. Salamanca, Salamanca, ¹⁹H. Esperit Sant, Barcelona, Spain, ²⁰H. 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
Abstract Number: 1304 • ACR Convergence 2020
Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort
Daniel Wendling¹, Clement Prati², Thierry Lequerre³, Corinne Miceli-Richard⁴, Maxime Dougados⁵, Anna Molto⁶ and Xavier Guillot⁷, ¹CHU Besançon, department of rheumatology, Besancon, France, ²Rheumatology, University Teaching Hospital, Besançon, France, ³Rheumatology, University Teaching Hospital, Rouen, France, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ⁷CHU Reunion, Saint Denis, Reunion
Background/Purpose: Uveitis is the most frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). DESIR is a prospective multicenter cohort of patients with early inflammatory back…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].